Aptose Biosciences (NASDAQ:APTO) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Friday morning,Benzinga reports. They currently have a $2.00 target price on the biotechnology company’s stock.

Separately, StockNews.com began coverage on Aptose Biosciences in a research note on Wednesday. They issued a “hold” rating for the company.

Aptose Biosciences Trading Up 3.2 %

APTO stock opened at $0.22 on Friday. The firm has a market cap of $13.24 million, a PE ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.48. The stock has a 50-day moving average price of $0.25 and a 200-day moving average price of $0.41.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.